

# **Chaos and Organization in Health Care**

**Thomas H. Lee, MD, and James J. Mongan, MD**

**The MIT Press  
Cambridge, Massachusetts  
London, England**

© 2009 Massachusetts Institute of Technology

All rights reserved. No part of this book may be reproduced in any form by any electronic or mechanical means (including photocopying, recording, or information storage and retrieval) without permission in writing from the publisher.

For information about special discounts, please email  
<special\_sales@mitpress.mit.edu>.

This book was set in Palatino by SNP Best-set Typesetter Ltd., Hong Kong.  
Printed and bound in the United States of America.

Library of Congress Cataloging-in-Publication Data

Lee, Thomas H.

Chaos and organization in health care / Thomas H. Lee, M.D. and James J. Mongan, M.D.

p. cm.

Includes bibliographical references and index.

ISBN 978-0-262-01353-6 (hardcover : alk. paper) 1. Medical care—United States. 2. Health care reform—United States. 3. Health facilities—United States—Administration. 4. Chaotic behavior in systems. 5. Organizational behavior. I. Mongan, James J. II. Title.

RA395.A3L414 2009  
362.1'04250973—dc22

2009013164

10 9 8 7 6 5 4 3 2 1

# Index

- Abbreviations, diagnostic, 72
- Academic medical centers, 120–123
- Accountable care organizations, 199
- Accreditation, NCQA, 59, 138–139
- ACE inhibitors, 115–116
- Activated consumer, 212
- Acute myocardial infarction, 25, 56, 102–103, 215
- Administration
  - complexity of, 209
  - costs, 22
  - and insurance, 41
- Administrative data, 215–216
- Admission rates, 134
- Adverse events, 16
- Aetna, 45, 153, 225
- Aging, 23
- AIDS, 27–28, 34
- AIDS and Its Metaphors*, 27
- Alcohol dependence, 6
- Ambulatory surgery, 101
- American Academy of Family Physicians, 138
- American Academy of Pediatrics, 138
- American College of Cardiology, 59–60
- American College of Physicians, 47, 138
- American Heart Association, 59–60
- American Osteopathic Association, 138
- Angioplasty, 27, 28
- Angiotensin-converting enzyme inhibitors, 28
- Antiretroviral therapy (ART), 27–28
- Article 99*, 99
- Aspirin, 25, 58, 115
- Asthma, 93, 117–118
- Astra Zeneca, 29, 33
- Atenolol, 57
- Autonomy, physician, 176–180, 237–239
- Avandia, 79
- Avastin, 34
- Axelrod, Robert, 192
- Baby boomers, 23
- Back pain, 44–45, 109
- Balloon angioplasty, 27
- Bar coding, 90, 102, 130
- Barium enema, 223
- Baseline cost, 20
- Behavioral economics, 191–192
- Beta-Blocker Heart Attack Trial (BHAT), 56–58, 60
- Beta-blockers, 25, 28, 56–60, 103
- Black, John, 104–105
- Blackford, John, 104
- Blood pressure, 63, 66, 137, 157
- Bodenheimer, Thomas, 25
- Boeing Company, 104
- Braunwald, Eugene, 58
- Breast cancer, 27, 29
  - medication costs, 34
  - reliability of treatment, 6
- Bridges to Excellence, 74–76, 156
- Brigham and Women’s Hospital, 87, 121, 128, 131
- Bristol-Myers-Squibb, 33
- Bundled payment methods, 205–207, 232–233
- Bypass surgery, 27, 97, 110–113, 171–172
- Call centers, 93–94
- Cancer, 63
  - breast, 6, 27, 29, 34
  - lung, 29
  - screening, 223

- Capitation, 114, 123–124, 146, 164–168, 207–209
  - and insurance companies, 123, 148, 167–168, 173–174, 199
  - and nontraditional interventions, 165–166
  - and pay-for-performance hybrid, 209
  - and physicians, 166–167
  - and providers, 166–168, 173–174, 199, 208, 241–242
  - and quality/efficiency, 148, 233, 241
- Care coordinators, 67, 140–141
- Career choices, medical, 12
- Care Management Institute, 114, 117
- Casalino, Lawrence, 94
- Case rate payment model, 146, 205–207
  - Geisinger CABG program, 112–113, 171–172
  - and quality/efficiency, 232–233
- Case studies
  - genetic markers, 29–33
  - multi-problem patients, 3–5, 211–212, 234
  - physician autonomy, 177–178
- Catastrophic protection, 43
- Cedars Sinai Hospital, 86
- Chemotherapy, 107–108
- Choice, patient, 166, 169
  - and capitation, 241–242
  - and narrowed network approach, 148–149
  - and quality, 234–235
- Cholecystectomy, 198
- Cholesterol, 103, 117
  - high-density lipoprotein, 33
  - testing, 171
- Chronic disease, 63, 66–67
  - chronic care model, 91–93
  - disease management, 153
  - and EMRs, 82–83
  - and patient cost exposure, 224–225
- Cleveland Clinic, 98
- Clinical data, 215–216
- Clinical information systems, 93
- Clinical integration, 246
- Clinic model, 119, 240
- Clinton, Bill, 99
- Clopidogrel, 25
- Closed systems, 119
- Colonoscopy, 223
- Common terminology, 72
- Commonwealth Fund Commission
  - report, 7, 61–62, 137–138
- Commonwealth Fund Survey of 2008, 18
- Communication
  - among physicians, 35
  - among providers, 65
  - and EMRs, 72–73
  - and multiple sites, 48
  - and patients, 49, 63–65, 110
  - with specialists, 48
- Community resources, 92
- Competition, 246
- Complex medical conditions, 3–5, 63, 67–68, 117, 153, 211–212
- Complication rates, 112–113, 235
- Computerized physician order entry (CPOE), 130
  - costs, 87, 188
  - and hospitals, 75, 86–88, 128
- Confidentiality, 49–50
- Conflict resolution, 191
- Congestive heart failure, 93–94, 134
- Consumer price inflation, 241
- Consumers, patients as, 212, 227, 236
- Continuous care, 67
- Coordinated care, 67, 140–141, 211–212
- Copayments, 149, 209, 236–237
- Coronary artery bypass graft (CABG), 97, 110–113
  - and case rates, 171–172, 206
  - mortality rates, 181, 217
- Coronary artery disease, 6, 116–117
- Costs, 20–26. *See also* Efficiency and aging population, 23–24
  - case rate approach, 112–113
  - chronic care, 93, 224–225
  - CPOE, 87, 188
  - disease management, 94, 153–154
  - doctors' and nurses' salaries, 12, 24, 189, 241
  - drug development, 33–34
  - electronic medication administration, 90, 188
  - and EMRs, 83–85, 188
  - expenditure patterns, 21–22
  - hospitals, 188–189
  - immunization, 34
  - increases in, 20–21, 164
  - indirect, 34
  - information systems, 188
  - insurance premiums, 198, 200–201
  - and market forces, 236–237

- and organized care, 65
- patient awareness of, 43–44, 218–220, 223–224, 231, 236
- personnel, 189
- public reporting on, 218–219, 231
- and quality of care, 26, 235–236
- technology and physical plant, 24–25
- Cost shifting, 189, 201, 209–210, 220–221, 225–226
- Crossing the Quality Chasm*, 5, 61–63
- CT scan, 26–27, 45, 184–185
  
- Data analysis, 144, 149–152. *See also* Public reporting
- Death rates, 28, 102–103, 117, 181–182, 215
- de Brantes, Françoise, 73
- Decision support, 92. *See also* Information systems
  - and efficiency, 65, 135, 171
  - and error reduction, 71–72, 130–131
- Deductibles, 149, 209
- Defensive medicine, 23
- Delivery organizations. *See also* Partners HealthCare System; Providers; Tightly structured organizations
  - Geisinger Health System, 84, 97–98, 109–113, 140, 171–172, 206
  - integrated, 99–100, 114, 119–120
  - Kaiser Permanente, 84, 98, 113–117, 148, 168
  - Veterans Health Administration (VHA), 89, 100–103, 131, 168
  - Virginia Mason Medical Center, 44–45, 98, 103–109, 192
- Demographic trends
  - and pace of change, 176
  - and rising health costs, 23
- Depression, 63, 94, 157
- Diabetes, 63
  - and cholesterol testing, 171
  - and chronic care programs, 93
  - insulin therapy, 6, 28
  - and physician report cards, 180–181
  - population-based care, 82–83, 113, 115–116, 132–133
  - recent medication for, 28
  - reliability of care, 132
  - and team practice, 66–67
- Diagnosis-related group (DRG) system, 205–206
- Discharge guidelines, 48, 116
  - medication, 87, 131–132
  - and PCP visits, 140
  - and public reporting, 243
- Disease management, 44, 93–95, 133–135.
  - See also* Population-based care
  - costs, 94, 153–154
  - defined, 152
  - diabetes, 82–83, 113, 115–116, 132–133
  - and fee-for-service payment, 134
  - and health plans, 94, 152–154
  - heart disease, 94, 116–117, 134
  - and information systems, 95
  - and performance incentives, 171
  - and subcapitation, 172
- Doctor-patient relationship, 16–18
- “Dose of Competition, A,” 201
- Drugs. *See* Medication
- Dual-earner couples, 13–14
  
- Eastern Kansas Veterans Affairs Medical Center, 102
- “Economic and Budget Issue Brief,” 219
- Education. *See also* Patient education and families, 13–14
  - physician, 10, 12
  - and reliability of health care, 7
- Efficiency, 65, 106–107. *See also* Costs and capitation, 148, 233, 241
  - and decision support, 65, 135, 171
  - and EMRs, 171
  - and fee-for-service payment, 195, 232
  - and negotiation, 191, 201
  - and payment methodologies, 170, 173, 232–233
  - and performance incentives, 147, 171, 232
  - and provider motivation, 220
  - and public reporting, 231
  - and testing costs, 135–136, 171, 185
  - and tiered networks, 149
  - and variation data, 183, 186
- Elderly, health costs of, 23–24
- Electronic medical records (EMRs), 63, 71–72, 75, 76–86, 139
  - and chronic disease, 82–83
  - costs of, 83–85, 188
  - diversity of, 11
  - and drug information, 79–82
  - and efficiency, 171
  - and error detection, 141–142
  - extent of use, 49, 76–77
  - FDA guidelines, 79

- Electronic medical records (EMRs) (cont.)  
 functions of, 76, 78, 84–85  
 in Partners HealthCare, 128–130  
 patient access to, 85, 159  
 and provider organization, 84  
 and public reporting, 243  
 and safety, 66–67, 131–132  
 and time management, 85  
 Vista, 101–102
- Electronic medication administration,  
 88–90, 188
- Electronic prescribing, 129–130, 171, 243
- Email, 211
- Emergency room visits, 223
- Emphysema, 58
- Employers, 154–158  
 and health plans, 155–158  
 and negotiation with providers, 198  
 and payment models, 195–196  
 and preventive care, 43, 154  
 and provider organization, 244–245  
 value-based purchasing, 155–156  
 workplace-based interventions,  
 156–157
- Enfuvirtide, 28
- Epidermal growth factor receptor  
 (EGFR), 30–31
- Episodes of care, 206
- Error reduction, 72, 86–87. *See also* Safety  
 and disease management, 152  
 and EMRs, 141–142  
 and medication administration, 89, 128,  
 130–131  
 and physicians' reputations, 180
- Evidence-based medicine, 50
- "Evidence on the Costs and Benefits of  
 Health Information Technology," 84
- Families, 13–14
- Fecal occult blood testing, 223
- Federal Trade Commission, 246
- Fee-for-service payment, 63, 140, 146  
 cap on increasing, 240–241  
 and chronic care programs, 93  
 and disease management, 134  
 and efficiency, 195, 232  
 and medical home model, 202  
 and nonphysician personnel, 139  
 and patients' health, 145  
 and provider organization, 147, 173,  
 195–196
- Flexible payment approach, 241, 244
- Flu shots, 109
- Fragmentation, health care, 37–51  
 EMRs, 49  
 and insurance companies, 38  
 and patient choice, 234  
 and patient-doctor relations, 39–40  
 and payment, 40–45  
 and practice patterns, 40  
 and providers, 45–50
- Galvin, Robert S., 73
- Game theory, 192
- Gefitinib, 29
- Geisinger Health System, 84, 97–98,  
 109–113, 140, 171–172, 206
- General Electric (GE), 73–74
- Generic drugs, 224, 236
- Genetic markers, 28–29, 32–33
- Global capitation, 114
- Government policy, 246–247
- Government underpayment, 209–210
- Grand Rounds, 10
- Group Health Cooperative of Puget  
 Sound, 92, 98
- Group practice, 55, 175–176. *See also*  
 Team practice
- Group purchasing, 43
- Guaranteed care, 112
- Haber, Daniel A., 30–32
- Hand washing, 187
- Harrison's Principles of Internal Medicine*,  
 10
- Health and Human Services, 213
- Health Care Financing Administration, 59
- Health care system, U.S. *See also*  
 Fragmentation, health care  
 Commonwealth Fund Commission  
 report, 7, 61–62, 137–138  
 Commonwealth Fund Survey of 2008,  
 18  
 increased utilization of, 24  
 Institute of Medicine reports on, 5  
 and other countries, 7, 20–21  
 overuse and misuse in, 8  
 RAND report of 2003, 6–7  
 reliability studies of, 5–7
- Health insurance plans, 144–145. *See also*  
 Insurance product design  
 and capitation, 123, 148, 167–168,  
 173–174, 199  
 and chronic care, 92

- and data analysis, 144, 149–152
- and disease management, 94, 152–154
- and disease specialization, 38, 44
- and drug coverage, 81–82
- and employers, 155–158
- extent of coverage, 43
- financial resources of, 144
- HDHPs, 221–228
- and hospitals, 196–197, 200
- managed care, 120–121, 123
- and Medicaid/Medicare patients, 192
- and member turnover, 43
- and mental health, 44
- motivation of, 144
- narrowed/tiered network products, 148–149, 156
- and national system, 41
- and patient choice, 148–149
- and payment models, 195–196
- and performance incentives, 147, 170, 200
- and physician autonomy, 238–239
- and provider organization, 189–190, 196–197, 199–202, 244–245
- and small providers, 196
- and testing, 45
- Health risk assessment questionnaires, 156–157
- Health savings accounts (HSAs), 221–223, 226
- Health Vault, 160
- Heart attack, 63
  - acute myocardial infarction, 25, 56, 102–103, 215
  - and aspirin, 58
  - and beta-blockers, 25, 28, 56–60, 103
  - coronary artery bypass graft (CABG), 27, 97, 110–113, 171–172, 181, 206
  - and public reporting, 216–217, 243
  - VHA study, 102–103
  - and workplace stress, 157–158
- Heart disease
  - and chronic care programs, 93
  - coronary artery disease, 6, 116–117
  - death rates, 28, 102–103, 117, 181–182, 215–216
  - and disease management, 94, 116–117, 134
- Heart Disease*, 58
- Heart valve replacement, 28
- HEDIS measures, 213
- Heparin, 89
- Hepatitis B, 15
- High-deductible health insurance plans (HDHPs), 221–228
- High Performance Medicine program, 125–137
- High-risk patients, 93–95
- HIV, 27–28, 34
- HMOs. *See also* Health insurance plans
  - beta-blockers as performance measure, 56, 59
  - and negotiation with providers, 198
  - and quality measures, 213
- Hodgkin's disease, 185–186
- Hospitals
  - admission rates, 134
  - and case rate model, 233
  - costs, 188–189
  - and CPOE, 75, 86–88, 128
  - deferred maintenance, 189
  - discharge guidelines, 48, 87, 116, 131–132, 140, 243
  - and DRGs, 205–206
  - inpatient problems, 87–88
  - and insurance companies, 196–197, 200
  - Leapfrog quality measures, 75–76
  - and managed care plans, 120–121
  - and mortality rates, 216
  - and payment incentives, 59
  - quality measurement and reporting, 59, 213, 215, 217
  - reduction of hospitalizations, 65, 199, 206, 235
  - relations with PCPs, 48
  - and safe medication administration, 88–90
  - teaching, 34
  - "Humanware," 63, 71, 75
- Hypertension, 63, 66, 137, 157
- Identification bracelet, 90, 130
- Illness as Metaphor*, 27
- Immunizations, 6, 34
- Incentives, 173, 191–192. *See also* Performance
  - and efficiency, 147, 171, 232
  - and flexible payment, 241
  - and health plans, 147, 170, 200
  - and hospitals, 59
  - medical home model, 232
  - pay-for-performance programs, 150–151, 170–171, 204, 232

- Independent practice associations (IPAs), 123–124
- Independent practice organizations (IPOs), 123
- Indirect costs, 34
- Individual mandate approach, 226
- Inflation, 241
- Influenza vaccination, 109
- Information overload, 71
- Information systems, 117. *See also*
  - Electronic medical records (EMRs) and chronic care, 93
  - computerized physician order entry (CPOE), 75, 86–88, 128, 130, 188
  - costs, 188
  - decision support, 65, 71–72, 92, 130–131, 135, 171
  - and disease management, 95
  - electronic medication administration, 88–90, 188
  - and government policy, 246
  - in Partners HealthCare, 126–132, 171
  - and patient participation, 110
  - and small practices, 188
  - Vista, 101–102
- Innovations. *See* Technological progress
- Institute for Healthcare Improvement, 60
- Institute of Medicine, 5, 62, 74
- Insulin therapy, 6, 28
- Insurance companies. *See* Health insurance plans
- Insurance premiums, 198, 200–201
- Insurance product design, 219–228
  - and cost shifting, 220–221, 225–226
  - health savings accounts (HSAs), 221–223, 226
  - high-deductible health insurance plans (HDHPs), 221–228
  - narrowed network products, 148–149
  - and patient choice, 234–235
  - tiered network products, 149, 156, 226–227
  - value-based purchasing, 155–156, 225–226
- Integrated delivery organization, 114, 119. *See also* Tightly structured organizations
- Integrated service network (ISN), 99–100
- Intensive care unit (ICU), 75
- Intermountain Health Care, 84, 98
- Internet
  - and clinician networks, 193–194
  - patient portals, 159
  - personal health records, 159–160
  - public reporting on, 213, 218
  - as source of physician knowledge, 10
- Interventions. *See also* Population-based care
  - cost of, 235
  - and CPOE, 87
  - documentation of, 112
  - and information systems, 93
  - misuse/overuse of, 8, 171
  - nontraditional, 165–166
  - and providers, 143
  - reliability of, 6, 35, 87
  - telephonic coaching, 135
  - workplace-based, 156–157
- In vitro fertilization, 27
- IPA model, 200
- Iressa, 29–32, 34
- Job strain, 157–158
- Joint Commission on Accreditation of Healthcare Organizations, 59
- Kaiser Permanente, 84, 98, 113–117, 148, 168
- Kaplan, Gary, 104, 106, 108
- Kinnick, Sue, 101–102
- Kizer, Kenneth W., 99–101
- Laparoscopic cholecystectomy, 26
- Leadership skills, 190–192
- Leapfrog, 75–76, 156, 213
- Life expectancy, 23
- Lindbergh, Charles, 51
- Lisinopril, 115
- Lovastatin, 115
- Low back pain, 44–45, 109
- Lung cancer, 29
- Lynch, Tom, 30–32
- Malpractice system, 23
- Mammography, 6, 103, 171
- Managed care plans, 120–121, 123. *See also* Health insurance plans
- Market forces, 211–228
  - and costs, 236–237
  - and insurance product design, 219–228
  - and public reporting, 132–133, 182, 212–219
- Mason, Tate, 104
- Massachusetts, 120–121, 123–125, 226



- Massachusetts General Hospital, 121, 131  
 Mayo Clinic, 98  
 McGlynn, Elizabeth, 6, 35  
 Media, health information in, 16  
 Medicaid, 135, 189, 192, 209, 237, 242  
 Medical home model, 172, 202, 207  
   incentives of, 232  
   and primary care physicians, 120, 137–141  
 Medical inflation, 241  
 Medical knowledge, explosion of, 10–11  
 Medical/Psychiatric High Risk Case Management Program, 153–154  
 Medicare, 197, 237, 242  
   and heart attack treatment, 59  
   and hospitalizations, 205–206  
   and mammography, 103  
   patient-physician interactions, 39  
   and providers' costs, 189, 192  
   spending per beneficiary, 40  
   underpayment by, 209–210  
 Medicare Advantage, 208  
 Medication  
   bar coding, 90  
   cost-effective, 44  
   and CPOE, 75, 86–88, 128  
   development costs, 33–34  
   diabetes, 28  
   effectiveness review of, 247  
   electronic administration of, 88–90, 188  
   and EMR information, 79–82  
   generic, 224, 236  
   heart disease, 25, 28  
   innovative, 27  
   insurance coverage of, 81–82  
   and safety, 88–90, 101–102, 130–132, 193  
   smart drugs, 29–32  
 MEDLINE, 10  
 Mental health, 44  
 Metformin, 28  
 Methodist Hospital, 89  
 Metoprolol, 57  
 Microsoft, 160  
 Mortality rates, 7, 28, 102–103, 117, 181–182, 215–217  
 MRI, 26–27, 45, 198  
 MULTIFIT, 116–117  
*Mycobacterium avium* complex disease, 27  
 Myocardial infarction, 25, 56, 102–103, 215  
 Nadolol, 57  
 Nakao, Chihiro, 107  
 Narrowed network insurance, 148–149  
 National Ambulatory Medical Care Survey, 46–47  
 National Committee for Quality Assurance (NCQA), 56, 74–75, 159  
   accreditation, 59, 138–139  
   HEDIS measures, 213  
 National Institute for Health and Clinical Excellence, 247  
 National Institutes of Health, 56–57  
 National Quality Forum, 159  
 Negotiation, 191, 198, 201  
 Networks of physicians, 55  
 “Never events,” 235–236  
*New England Journal of Medicine*, 10  
 Nexium, 80–81  
 Nonnucleoside reverse transcriptase inhibitors, 28  
 Nonphysician personnel, 92, 139–141, 207, 238  
 Nurses  
   as care coordinators, 67, 140–141  
   and disease management, 94, 134, 152–153  
   and medication administration, 90  
   and population-based care, 116–117  
   salaries of, 24, 189, 241  
   shortage of, 198  
   telephonic coaching, 135  
 Obama administration, 246–247  
 Office visits, 17, 47–48, 84, 140  
 Omeprazole, 81  
 Organized care, 63–65, 229  
 Parsons, Talcott, 220  
 Partners HealthCare System, 43, 78, 84, 120–137, 157, 170  
   and capitation, 165, 167  
   corporate organization of, 122  
   Heart Failure Program, 134  
   High Performance Medicine, 125–137  
   information systems in, 126–132, 171  
   medication administration in, 130–132  
 Partners Community HealthCare, Inc. (PCHI), 123–124  
   and pay-for-performance contracts, 124–125, 131, 137, 141, 147, 171  
   Signature Initiatives, 125

- Partners HealthCare System (cont.)  
 and systems theory, 193  
 testing efficiency, 135–137  
 and variation data, 185–186
- Pasteur, Louis, 32
- Patient education  
 and chronic disease, 66, 92  
 and complex conditions, 67  
 and disease management, 94–95, 117  
 Internet portals, 159  
 personal health records, 159–160  
 reliability of, 6
- Patient identification bracelet, 90, 130
- Patients  
 as activated consumers, 212, 227, 236  
 and choice, 148–149, 166, 169, 234–235, 241–242  
 with chronic disease, 63, 66–67, 92  
 and communication, 49, 63–65  
 with complex medical conditions, 63, 67–68  
 and consumer organizations, 158–159  
 and cost awareness, 43–44, 218–220, 223–227, 231, 236  
 and disease management programs, 152–153  
 doctor-patient relationship, 16–18  
 and EMRs, 85, 159  
 expanded treatment population, 26  
 expectations and experience of, 18, 35, 159  
 frequency of physician visits, 17  
 high-risk, 93–95  
 and information systems, 110  
 and medical home, 137  
 and organized care, 65, 245  
 participation of, 35, 73  
 and performance data, 151  
 and public reporting, 214, 218–219  
 relations with physicians, 16–18, 39–40  
 and systemic change, 164  
 uninsured, 135  
 worried/unworried well, 63, 68–69
- Patient safety  
 Institute of Medicine reports on, 5  
 and medication administration, 88–90  
 physicians' report on, 8
- Patterns of practice, 40, 185
- Pay-for-performance programs, 124–125, 131, 137, 141, 202–205  
 and capitation, 209  
 and incentives, 150–151, 170–171, 204, 232  
 limitations of, 203  
 and patient populations, 204–205  
 and provider organization, 146–147, 203  
 and quality/efficiency, 231–232  
 and small providers, 204
- Payment, 40–45, 164–174, 195–210. *See also* Capitation; Fee-for-service payment  
 bundled payment, 205–207, 232–233  
 case rate model, 112–113, 146, 171–172, 205–207, 232–233  
 and compensated activities, 42  
 copayment and deductibles, 149  
 and efficiency, 170, 173, 232–233  
 and employers, 195–196  
 flexible payment approach, 241, 244  
 group purchasing, 43  
 and health plans, 195–196  
 medical home model, 120, 137–141, 172, 202, 207, 232  
 models of, 145–147  
 in narrowed/tiered networks, 148–149  
 and negotiation, 44  
 and organizational evolution, 169–170  
 patient awareness of, 43–44  
 payment dysfunction, 209–210  
 problems of, 168–169  
 prospective, 164–165, 171–174, 235, 248  
 and provider organization, 145–147, 165, 168–169, 173–174, 195–196, 199–200, 202–204, 239–242  
 single-payer system, 209, 237  
 and small providers, 170, 204  
 subcapitation, 146, 148, 172–174  
 and technological progress, 148  
 and testing, 45
- Penn State University, 109
- Performance. *See also* Public reporting improvement, 60  
 incentives, 147, 150–151, 170–171, 173, 191–192, 200  
 measurement, 56, 59, 179–182, 243–244  
 and variation data, 183–187
- Perlin, Jonathan, 102
- Personal health records, 159–160
- Personalized care, 67
- Personnel costs, 189
- PET scan, 26–27, 186
- Pfizer, 33
- Pharmaceutical industry, 22

- Pharmacy, tiered, 236–237
- Pharmacy benefit management, 44
- Physical therapy, 45
- Physician-hospital organizations (PHO), 123–124, 200
- Physician Office Link program, 138–139
- Physicians. *See also* Primary care physicians (PCPs)
- accountability to colleagues, 187
  - accreditation of, 138–139
  - as all-knowing healers, 9–10, 50–51
  - autonomy of, 176–180, 237–239
  - Bridges to Excellence standards, 74–76
  - and capitation, 166–167
  - and case rate model, 233
  - computerized support for, 65
  - continuing education of, 10
  - coordination among, 35
  - daily routines of, 8–9
  - decision support for, 65, 71–72
  - and disease management programs, 152–153
  - doctor-patient relationship, 16–18
  - and DRGs, 205–206
  - duration of patient visits, 17
  - and EMR adoption, 129
  - and evidence-based medicine, 50
  - and extra testing, 23
  - and group practice, 55
  - and lifestyle, 12–13
  - and managed care plans, 123
  - and mortality rates, 217
  - and performance incentives, 147, 170, 173, 200
  - and performance measurement, 179–182, 244
  - and proactive care, 91
  - and public reporting, 213, 215, 244
  - relations with patients, 16–18
  - report cards, 51
  - salaries of, 12, 24
  - and team practice, 46–47
  - and technological progress, 35, 39
  - and testing data, 135–136
  - tunnel vision of, 177
  - and variation data, 183–187
  - workload of, 72
- Pneumocystis jirovecii* pneumonia, 27
- Pneumonia, 215
- Policy, government, 246–247
- Policymakers, 246–247
- Population-based care, 23, 67–69. *See also*
- Disease management
  - ALL program, 115–116
  - asthma, 117–118
  - chronic care model, 91–93
  - complex medical conditions, 117
  - coronary artery disease, 116–117
  - and CPOE, 87
  - diabetes, 82–83, 113, 115–116, 132–133
  - disease management, 44, 93–95, 133–135, 152–154
  - and EMRs, 82–83
  - in Partners HealthCare, 132–133
  - and performance incentives, 147
  - and physician report cards, 181
  - and preventive programs, 235
  - and provider organization, 199
- Portals, patient, 159
- Prescription drugs
- and HDHPs, 224–225
  - increase in use of, 16
- Prescriptions
- electronic, 129–130, 171, 243
  - variation in, 183
- Preventive care, 43, 154, 235. *See also*
- Interventions; Quality
- Price transparency, 218–219
- Prilosec, 81
- Primary care physicians (PCPs), 12
- characteristics of care, 138
  - and discharge summaries, 48
  - and EMRs, 77
  - and hospitals, 48
  - and information management, 14–17
  - and lifestyle, 12
  - and medical home model, 120, 137–141, 232
  - and missing data, 15
  - and patient load, 15, 39–40
  - and specialists, 47–48
  - and VHA, 100
  - and worried well, 68
- Privacy, 160
- Proactive care, 66, 68, 91
- Proceduralist, 47–48
- Process improvement, 192–193
- Progress. *See* Technological progress
- Prometheus Payment, Inc., 206
- Propranolol, 56–57
- Prospective payment, 164–165, 171–174, 235, 248
- Prospect theory, 191–192, 204

- Protease inhibitors, 28
- ProvenCare, 111
- Providers, 45–50. *See also* Delivery organizations; Physicians; Small practices; Tightly structured organizations
- and capitation, 166–168, 173–174, 199, 208, 241–242
- and chronic care, 92
- communication between, 65
- costs, 188–190, 192–193, 198–199
- and employers, 155–156, 158, 244–245
- and EMRs, 84–85
- and fee-for-service payment, 195–196
- and insurance companies, 189–190, 196–197, 199–202, 226–227, 244–245
- and interventions, 143
- leadership role of, 229–230
- and market forces, 220
- and negotiation, 191
- and patient involvement in care, 159
- and payment models, 145–147, 169–174, 195–196, 239–242, 247–248
- and performance data, 151–152, 244
- provider organization, 55, 147, 173, 175–176, 195–196, 229, 241, 242, 244–245
- and public reporting, 215–216, 227, 231, 244, 247
- and purchaser ambivalence, 196–202
- responsibility of, 63
- size of, 167
- Public reporting, 156, 247. *See also* Performance
- on cost, 218–219, 231
- and health plans, 149–152
- and heart attacks, 216–217, 243
- and hospitals, 59, 213, 215, 217
- and integration of care, 243
- and market forces, 132–133, 182, 212–219
- mortality rates, 215
- patient awareness of, 214
- and physicians, 213, 215, 244
- by providers, 227
- on quality, 215–218, 231, 233, 243–244
- and severity of illness, 214, 216
- Pulmonary disease, 58
- Pulmonary embolism, 14
- Quality
- and costs, 26, 235–236
- and flexible payment, 241
- improvement, 60, 114–116, 236
- and negotiation, 201
- and patient choice, 234–235
- and payment methodologies, 170, 173, 232–233
- and physician autonomy, 237–239
- and provider motivation, 220
- public reporting on, 215–218, 231, 233, 243–244
- and variation data, 183, 186
- Quality measurement, 63
- and beta-blockers, 56, 59–60
- and HMOs, 213
- and hospitals, 59, 213, 215, 217
- Leapfrog measures, 75–76
- and patient outcomes, 215, 217
- and VHA, 102
- Radiology testing, 135, 171, 183–186
- RAND report of 2003, 6–7
- Registries, 93
- Reinertsen, James, 239
- Reliability of care, 5–7
- alcohol dependence, 6
- breast cancer, 6
- diabetes, 132
- and education, 7
- interventions, 6, 35, 87
- and race, 7
- Rich, Michael, 134
- Risk adjustment, 216
- Robbins, Kate, 29–32
- Rona, J. Michael, 104, 106
- Safety, 74
- and CPOE, 87
- and EMRs, 66–67, 131–132
- and information transfer, 131–132
- and medication administration, 88–90, 101–102, 130–132, 193
- and performance incentives, 171
- safe practices, 75
- Salaries
- nurses, 24, 189, 241
- physicians, 12, 24
- Saving Your Life*, 16
- Screening, cancer, 223
- Senior citizens, 18
- Sick role, 220–221
- Sigmoidoscopy, 223
- Signature Initiatives, 125
- Single-payer system, 209, 237

- "Six Sigma Design Team," 73–74  
 "Skin in the game," 219–220  
 Small practices, 119–120, 140–141, 195, 245  
   and information systems, 188  
   and insurance companies, 196  
   and pay-for-performance, 204  
   and payment methodologies, 170  
   and performance incentives, 147, 170  
 Smart drugs, 29–32  
 Smart pumps, 130–131  
 Smoking cessation, 103, 235  
 Social network analysis, 193  
 Sontag, Susan, 27  
 Specialization, 11  
   and lifestyle, 12–13  
   physician visits, 47–48  
   and primary care, 12  
   proceduralist, 47–48  
   and technological progress, 35  
 Statins, 25, 28, 117–118, 198  
 Statistical techniques, 181–182  
 Steele, Glenn, 110  
 Stents, 27  
 Stop-loss insurance, 208  
 Strategic planning, 190  
 Streamlining treatment, 107–108  
 Subcapitation, 146, 148, 172–174  
 Sulfonylureas, 28  
 Surgery  
   minimally invasive, 28  
   reducing complications in, 102  
   surgical specialties, 12  
 Sweden, 27  
 Systems theory, 193  
  
 Tax shelter, 222–223  
 Teaching hospitals, 34  
 Team practice, 46–47, 51, 71–72  
   and accountability, 187  
   and case rates, 172  
   and chronic disease, 66  
   and complex medical conditions, 67  
   and medical home model, 207  
   and physician autonomy, 178–180, 238  
   and physician compact, 104  
*Technological Change and the Growth of Health Care Spending*, 20–21  
 Technological progress, 19–36  
   case study, 29–33  
   challenges of, 34–36  
   costs of, 20–26  
   effectiveness review of, 247  
   and health care delivery, 38  
   heart disease, 28  
   HIV infections, 27–28  
   medication, 27, 29–32  
   and payment, 148  
   and systemic change, 58–59, 163–164  
 Terminology, common, 72  
 Testing  
   cost-effectiveness of, 135–136, 171, 185  
   and HDHPs, 223  
   and payment, 45  
   and performance incentives, 171  
   variation data, 40, 183–186  
 Tiered network insurance, 149, 156, 226–227  
 Tiered pharmacy formularies, 236–237  
 Tightly structured organizations, 147–148. *See also* Delivery organizations; Providers and capitation, 208  
   extent of, 195  
   integrated delivery organization, 114, 119  
   integrated service network (ISN), 99–100  
   and patient data, 150  
   and payment, 165, 168–169, 173  
 Tit-for-tat approach, 192  
*To Err Is Human*, 5  
 Torcetrapib, 33  
 Toyoda, Sakichi, 105  
 Toyota Production System, 104, 106, 193  
 Toyota Way, 105–106  
 Trust, 16–18  
 Tuberculosis, 27  
 Tumor markers, mutations of, 31  
 "Tyranny of the Urgent," 92  
  
 Underpayment, government, 209–210  
 Uninsured patients, 135  
 Universal patient identification number (UPIN), 49  
 Unworried well, 63, 68–69  
 Urinary tract infection, 14  
  
 Vaccination, influenza, 109  
 Value-based purchasing, 155–156, 225–226

- Variation data, 40, 183–187, 193, 238
- Veterans Health Administration (VHA),
  - 89, 97–103, 131
  - and capitation, 168
  - improvements in service, 100–102
  - quality of care, 102–103
  - Vista, 101–102
- Veterans Integrated Service Network (VISN), 99–100
- Virginia Mason Medical Center, 44–45,
  - 98, 103–109, 192
- Visits
  - emergency room, 223
  - office, 17, 47–48, 84, 140
- Vista (Veterans Health Information System and Technology Architecture), 101–102
  
- Wagner, Edward H., 92
- WebMD, 156–157
- Weight loss surgery, 28
- Worried well, 63, 68